Arch Hits 52-Week High on News

Arch Biopartners Inc. (V.ARCH) hit a new 52-week high of $5.05 on Wednesday. Arch announced today that its lead drug candidate, LSALT Peptide will enter the Canadian Treatments for COVID-19 human trial, a multi-centre adaptive, randomized, open-label, controlled study being conducted in 65 hospitals across Canada, in conjunction with the World Health Organization’s SOLIDARITY trial, in collaboration with countries around the world and with support from the Canadian Institutes of Health Research-funded Canadian Network of COVID-19 Clinical Trials Networks. LSALT will be evaluated in the Canadian trial.

Alpha Lithium Corporation (V.ALLI) hit a new 52-week high of $1.67 on Wednesday. No news stories available today.

Inventronics Limited (V.IVX) hit a new 52-week high of $2.70 on Wednesday. No news stories available today.

Read:

• Oncology Drug Developers Looking at Significant Projected Growth Through 2030

• Plant-Based Meats Continue to Sprout Growing Revenues on Year-Over-Year Basis

• No Apparent Need to Panic Over Omicron as Vaccine Developers Are on the Case

• Plant-Based Meats Market Projected to Hit $162 Billion by 2030, as New Products Launch

• Innovations in Plant-Based Protein Products Supplying the Food Industry’s Strongest Trends